The Power of Patient-Reported Outcomes Measures in Value-Based Care

By João L. Carapinha

November 3, 2023

Patient-Reported Outcomes Measures (PROMs) have emerged as a pivotal tool in healthcare. Healthcare settings have applied PROMs in numerous instances since the advent of Value-Based Care (VBC), gaining valuable insights into patients’ perceptions of their health and treatment outcomes.

 

PROMs in VBC

According to the FDA, PROMs are “reports coming directly from patients about how they feel or function in relation to a health condition and its therapy, without interpretation by healthcare professionals or anyone else.” Essentially, the definition emphasizes patient-centred care, where patients’ experiences and outcomes are central to healthcare delivery.

However, this begs the question: Are the current methods of capturing PROMs sufficient, or can we leverage today’s advanced technologies to optimise this process? The answer lies in the potential of artificial intelligence (AI) and electronic Patient-Reported Outcomes (ePROs).

 

Enhancing PROMs with AI and ePROs

Integrating PROs can significantly improve the patient journey, from symptom screening to treatment planning. This approach enables continuous feedback, providing real-time evidence of outcomes without the need for numerous follow-ups. The dynamic nature of this process also improves the perceived value of the cost per episode (CPE) for the patient.

AI tools can augment this area further by providing tailored support based on the severity of illness, eliminating the inefficiencies and frustrations caused by inappropriate care levels. For instance, an oncology trial in 2016 utilised a web-based symptom reporting system to automatically alert clinicians about reported symptoms. The system, although not AI-based, proved cost-effective, improved patient survival, reduced emergency visits, and enhanced the quality of life (QoL).

The Future of PROMs in Healthcare

NICE stated that evaluation of such solutions is necessary in the future. However, one must not lose sight of the patient’s perspective amidst the rush towards a digital space.

Previous articles discussed the risk of these solutions lacking a patient-centred approach and provided other “moonshot” solutions to address this. The lack of patient or person-centred care dehumanises the care continuum which poses a risk to VBC. 

The potential of a PRO model lies in its dual approach: as an input into an AI model predicting an outcome, and as an output from an AI model predicting changes in symptoms or QoL. This captures the lived experience of the patient. In a pilot study, the system demonstrated its ability to predict the likelihood of patients achieving Minimal Important Clinical Difference (MCID). This was after a Total Knee Arthroplasty (TKA).

However, the design’s fragmented nature and lack of representation of the diverse population it serves remain significant challenges. Biases in AI and validated system training limitations can skew the model. This could perpetuate many of the inherent issues. 

To mitigate these challenges, it’s recommended that PROs become standard practice, prioritised, and incorporate the patient experience as a key metric. Careful consideration must be given to PROMs integration. The focus must be user-centred to ensure ease of use and optimised workflows. International guidelines such as The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) highlight elements of good design.

The inclusion of these systems has the potential to improve health and QoL by supporting better and faster patient-centred care. To ensure clinician utilization and patient integration, we need to take several steps. These steps will help in achieving a high-value outlook. Patient-Reported Outcomes Measures, augmented by these tools, can significantly influence healthcare system navigation, optimising the continuum of care, and improving outcomes.

Reference url

Recent Posts

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

essential prescription drugs
       

Canada Launches Consultation for Essential Prescription Drugs List

💊 Are you curious about how Canada plans to make essential prescription drugs accessible for everyone?

Canada’s Drug Agency has launched a national consultation to create a list of essential prescriptions that aim to ensure equitable access, improve health outcomes, and reduce costs. This initiative marks a key step towards universal pharmacare and highlights the importance of evidence-based practices in healthcare.

Dive into our latest article to learn more about the implications for patients, policymakers, and the broader healthcare system!

#SyenzaNews #healthcare #HealthEconomics

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.